Interactive Transcript
0:02
Hello, and welcome to Noon Conference hosted by Modality.
0:06
Noon Conference connects the global radiology community through free live
0:09
educational webinars that are accessible for all, and is an opportunity to learn
0:13
alongside top radiologists from around the world.
0:17
Today, we are honored to welcome Dr.
0:19
Lacey McIntosh for a lecture entitled Atypical Lung Cancers. Dr.
0:23
McIntosh is an associate professor of radiology at UMass Medical School and
0:28
specializes in cancer and molecular imaging.
0:31
She currently serves as the Assistant Program Director, Diagnostic Radiology
0:36
Residency, and the Division Chief, Oncologic and Molecular Imaging at UMass
0:41
Memorial Medical Center. She loves teaching and working with residents.
0:45
At the end of the lecture, please join Dr.
0:47
McIntosh in a Q&A session where she will address questions you may have on today's
0:51
topic. Please remember to use the Q&A feature to submit your questions so we can
0:55
get to as many as we can before our time's up.
0:57
With that, we are ready to begin today's lecture. Dr.
1:00
McIntosh, please take it from here.
1:07
Great. Thank you so much for the warm introduction. I'm so happy to be here.
1:12
Thank you for having me. So yes, today we're going to talk about atypical lung
1:17
cancer.
1:20
I have a few disclosures for clinical trial reads and curriculum creation, but
1:24
nothing relevant to this talk. So today we're going to review some historical lung
1:29
cancer facts and trends, as well as explore typical and atypical features of lung
1:35
cancer. We're going to review specifically radiologic findings of typical and
1:40
atypical lung cancers.
1:44
So when approaching atypical lung cancer, we first must define what typical lung
1:49
cancer is, but how we define typical isn't exactly hard and fast, right?
1:54
It's a fluid and relative concept, and it considers different elements.
2:01
One of these elements is time. What's typical today was probably not typical in the
2:06
past and may not be typical in the future.
2:08
What shapes our perception of typical is contextual, it's changing, sometimes
2:13
cyclical, so we must sort of reconcile the past and the future, understand the
2:18
present to reexamine what we know about lung cancer in light of evolving evidence
2:22
to redefine for us today what is typical and thus atypical.
2:28
Subject to this constant change itself is indeed lung cancer.
2:32
Just a little more than a century ago, lung cancer was extremely rare and certainly
2:37
fell into the category of atypical neoplastic diseases.
2:41
We've seen changes over time. Just diving back a little bit into the history, while
2:45
the late 1800s showed some of the first documented evidence of lung cancer, it
2:49
certainly wasn't the beginning. As early as 1500, miners in Central and Eastern
2:54
Europe developed Bergbrand, Scheinberg Mountain sickness, later identified as lung
2:59
cancer. Certain regions were identified as death pits, where virtually all workers
3:04
got sick. People started to take the time to examine causation, later attributing
3:08
the sickness to arsenic, radium, and radon gas exposures.
3:12
In the US, lung cancer reports were very rare prior to the early 1900s, and some of
3:17
the first reports were linked to uranium and mining in Colorado, which were pursued
3:21
for manufacturing atomic bombs and building a nuclear arsenal.
3:28
By the 1940s and '50s, cigarette smoking had become extremely popular, endorsed by
3:32
many, including doctors and celebrities, and lung cancer rates were on the rise.
3:36
Tobacco companies were effective in their propaganda, calling the links to lung
3:40
cancer controversial and demanding more research, despite case-controlled studies
3:44
and internal research supporting the link.
3:48
Fast-forward to today, lung cancer is the most commonly diagnosed cancer and
3:52
leading cause of cancer deaths worldwide.
3:55
We do, however, note a more recent slight decline in rates that further emphasizes
3:58
the fluidity in our perception of what is typical for lung cancer.
4:04
So in this presentation today, we're going to look at what makes lung cancer
4:07
typical and thus atypical from multiple different perspectives, including the types
4:12
of patients with lung cancer, the anatomic location and histology,
4:18
radiographic appearance, metabolic and molecular behavior,
4:23
to things like detection, management, and finally, prognosis.
4:29
We'll examine the fluid and dynamic aspects of each of these.
4:33
So let's start with patients we see with suspected or proven lung cancer in our
4:37
clinics. This is who we would consider a typical patient with lung cancer, an older
4:43
cigarette-smoking male. However, we are also encountering increasing numbers of
4:48
atypical patients with lung cancer.
4:53
Included in these groups are those with secondary exposures.
4:57
An interesting group of patients we see with lung cancer are non or low smokers
5:01
with asthma who develop carcinoid tumors, itself an atypical lung cancer with a
5:06
potential paradoxical protective effect from smoking.
5:10
We also see patients with genetic predispositions, those with a family history of
5:14
lung cancer, and females who have unique sex-specific risks.
5:19
In particular, a group of East Asian female never smokers with lung cancer has been
5:23
receiving increasing attention.
5:26
We can see in this graph from a recent study in Taiwan showing that despite stable,
5:31
low smoking rates, we have a notable increase in lung cancer incidents over
5:37
time, which is mainly driven by adenocarcinoma.
5:42
Finally, as patients live longer with better outcomes for their lung cancer, it's
5:47
becoming less atypical to diagnose second, third, or more lung cancers in the same
5:51
patient.
5:55
Let's now discuss the anatomic location and histology of lung cancer.
6:01
We've certainly noticed a shift in the typical anatomic location of lung cancers,
6:06
primarily triggered by changes in cigarette composition and smaller particulate
6:10
pollution. Early filterless cigarettes deposited particles centrally in the airways
6:16
and typically caused more central lung cancers.
6:19
The introduction of filters in cigarettes changed this pattern.
6:22
Smokers needed to inhale more deeply and forcefully, driving deposition deeper into
6:27
the lung, with filters blocking the larger particles, but allowing smaller
6:31
particles to travel further into the lung.
6:34
This resulted in more peripherally located lung cancers.
6:37
So we can see now that what was previously atypical has become typical with this
6:43
peripheral distribution.
6:48
As for histology, the three main types of typical histologies
6:55
compromising the majority of lung cancers that we see are usually adenocarcinomas,
7:00
squamous cell carcinoma, and small cell carcinoma.
7:03
These three together make up approximately 80% of lung cancers that we see in our
7:08
clinics. However, there are many less typical histologies such as carcinoid,
7:14
large cell, sarcomatoid carcinoma, which have emerged, shifting this distribution
7:19
of histologies. Both the increasing numbers and resulting shifts should raise our
7:23
awareness for these atypical lung cancer histologies.
7:30
Molecular profiling of lung cancers has become increasingly important.
7:34
Just two decades ago, this was neither typical nor atypical, but simply
7:39
nonexistent. However, today, gene sequencing is of paramount importance, not only
7:44
for the diagnosis, but arguably more important for the selection of targeted
7:49
treatments, and this has become a typical mainstay in the workup of lung cancer
7:54
today.
7:57
With that, we come to the central part of this presentation regarding the
8:02
radiographic appearances of lung cancer.
8:07
Typical appearances of lung cancer usually consist of a nodule that is solid,
8:13
sub-solid, or part solid. Spiculation and pleural retraction are common features
8:19
of malignancy. You can see here this large tumor, this mass has a lobulated
8:26
contour with maybe some areas of microlobulation.
8:29
The next panel shows a mixed solid and ground-glass component nodule, and then the
8:35
third shows a mostly solid nodule with definite spiculation and some pleural tags
8:41
at the inferior aspect. And then the last two show pleural retraction and visceral
8:48
indentation with spiculation in the last panel.
8:55
But not all cancer follows these rules, such as this atypically benign-featured
9:00
nodule, which demonstrates a rectangular shape with fairly smooth and well-defined
9:05
margins However, on follow-up, this nodule later declared itself malignant
9:11
and was found to be a small cell carcinoma.
9:14
You can see the transformation from somewhat benign features to
9:20
microlobulated and lobulated contours with spiculations and pleural indentation at
9:26
the right lateral aspect.
9:31
We also see here a typical irregular cystic lesion, which over time showed
9:36
increasing complexity, which was also found to be malignant.
9:41
This area of cystic lung cancers is emerging and
9:46
increasingly being incorporated into our lung cancer screening nodule
9:51
management guidelines, which is very important because these are sort of newly
9:57
recognized as being malignant potential.
10:03
We see these atypical complex cystic lung cancers which show varying degrees of
10:07
cystic and solid components. The lesion on the left I would describe as
10:12
predominantly cystic with some areas of wall thickening, some of which is smooth,
10:17
where the yellow arrow is, and some of which is more nodular and irregular, where
10:21
the red arrow is. The lesion on the right is, I think, more complex, but
10:26
predominantly solid with prominent cystic components, but this also demonstrates
10:31
features of spiculation and irregular margins as well.
10:37
Cavitation in a nodule can be suggestive of infection, but can also be seen with
10:43
malignancy, as was the case for this small squamous cell carcinoma.
10:52
This left lower lobe consolidation has a typical appearance of pneumonia.
10:56
We see consolidation with air bronchograms on the first image, and then we can
11:02
see an increase in these findings on the second image.
11:05
This did not respond to antibiotics and actually turned out to be a mucinous
11:10
adenocarcinoma. Non-mass-like cancers mimicking infection are atypical in
11:15
appearance.
11:19
Lung cancers that occur in the setting of background architectural distortion can
11:23
also appear atypical, as in this case of an intensely FDG avid right upper lobe
11:29
lung cancer. This demonstrates a finger-like projection at the right lateral
11:33
aspect, which was due to growing around areas of bullous emphysema.
11:42
And perhaps the most atypical presentation of lung cancer is when it arises within
11:46
hilar or mediastinal lymph nodes and without an actual primary lung lesion, as we
11:51
see here on this PET-CT.
11:57
Beyond static morphology, we must also examine dynamic morphology or changes in
12:02
morphology over time.
12:05
Lung cancer typically grows in two patterns, either aggressive and growing quickly
12:10
or more indolent, slow-growing spectrum lesions that develop over years, with
12:14
changes in density sometimes being more notable than changes in size.
12:19
Atypical growth patterns may include long periods of stability followed by rapid
12:24
growth,
12:25
hyper-aggressive growth and spread, which sometimes can be confused for infection
12:31
because it's moving so quickly, or simply unexpected or unusual changes in
12:36
behavior.
12:39
Let's look at a few examples. So this type of unexpected dynamic morphology is
12:44
depicted here, where we have an atypically behaving malignant nodule, which showed
12:50
a relatively long period of stability with sudden rapid growth.
12:53
You can see between 2021 and 2023, it's really minimal change in this small,
12:59
mostly solid nodule. But between the same two-year time interval between 2023 and
13:05
2025, we have rapid increase in size of this nodule, which is
13:11
definitely more doubled in size, maybe more like five times or six times its
13:15
original size.
13:17
So this is sort of atypical dynamic morphology for malignancy.
13:25
Here we have a case of a lung cancer patient who experienced a delay in care during
13:30
workup and required a new baseline PET after two months.
13:36
And unfortunately, this showed atypically aggressive, widespread metastases.
13:42
So this is what falls in that category of sort of hyper-aggressive growth.
13:49
And finally, we have a case of typical and then atypical appearance of what was a
13:54
biopsy-proven hamartoma,
13:57
which had been stable over many years leading up to 2019, but then in 2025 started
14:02
showing interval growth, more lobulation at the margins, and then on soft tissue
14:07
windows, you can appreciate this aggressive chest wall invasion, which reflects a
14:12
malignant degeneration or transformation of this nodule.
14:18
Multiplicity of nodules or masses is typically suggestive of infection or
14:22
metastases and isn't usually indicative of a primary lung cancer.
14:27
But sometimes we do see multifocal cancers affecting the lung of similar or
14:32
differing histologies.
14:36
These images are all from a single CT exam in one patient.
14:40
While not exactly typical, it is becoming less rare to see multifocal synchronous
14:45
primary lung cancers, particularly in smokers, due to field effect, as we see in
14:50
this patient with multifocal synchronous primary adenocarcinoma spectrum-type
14:54
lesions. We really sort of run the gamut here with lesions
15:00
that look to be mostly
15:03
ground-glass density versus the first panel in the top right shows
15:08
predominantly ground-glass, but with a solid component at the right lateral aspect.
15:13
And then the bottom row is showing sort of increasing punctate solid components,
15:17
and then over to the last two panels, we see increasing solid component, and the
15:23
very last panel is predominantly solid with spiculation.
15:27
So
15:29
I wouldn't call this the typical presentation, but I think it's becoming less rare
15:34
to see, as patients live longer, multiple lung cancers diagnosed in the same
15:39
patients.
15:44
Here's another atypical presentation of multifocal synchronous primary lung
15:48
cancers, but in this case, we have lesions that have differing cystic and solid
15:54
features, which are suggestive of varying histologies.
16:02
Another case of an atypical lung cancer is this adenocarcinoma that was
16:06
incidentally detected on a staging workup for metastatic bladder cancer.
16:11
So you can see this is a mixed solid and ground-glass nodule, which is in the
16:17
background of multiple more solid and well-defined metastases throughout
16:23
the lungs that you can appreciate on the MIP here on the right.
16:31
Here's another example of these atypical bilateral oddly symmetric upper
16:37
lobe lung adenocarcinomas. Sort of interesting that we see them both on the same
16:42
axial slice. These were incidentally detected on a staging PET for a left
16:47
ureteral malignancy with retroperitoneal adenopathy.
16:53
You can see the findings here.
16:58
So important take-home points regarding the radiographic appearance for static
17:03
morphology. There really is no one-size-fits-all model to be able to identify all
17:08
lung cancers. Benign features don't necessarily indicate benign histology.
17:14
We must remember that cystic lesions can also be malignant.
17:18
Lung cancers can have unexpected or bizarre appearances, especially when occurring
17:23
in the setting of altered background architecture.
17:27
We must also consider dynamic morphology.
17:30
Lung cancers do not always follow the expected growth and behavior trends.
17:35
Finally, multiplicity. The presence of multiple nodules doesn't always suggest
17:39
infection or metastasis. It's becoming more common to see multiple cancers
17:44
affecting the lung of same or different types.
17:51
All right. Now let's look at metabolic and molecular behavior of lung cancers.
17:58
This is a typical metabolic behavior of a left lower lobe cavitary lung cancer on
18:03
FDG PET-CT. We see a large mass with intense tracer uptake corresponding with solid
18:09
tissue. This patient happens to have a cavitary component to their cancer.
18:17
As camera technology improves, we tend to apply FDG analysis to smaller lung
18:21
cancers. However, uptake in these smaller cancers might be very low or not
18:27
perceptible at all, in stark contrast to the typical uptake shown in the previous
18:31
slide. It's important to account for small size and to adjust avidity expectations
18:37
during PET interpretation of small nodules, particularly when they demonstrate
18:41
suspicious CT morphology, as shown in this case. This is a very small nodule.
18:45
I think it measured about six millimeters.
18:48
And you can see on the FDG PET that there's appreciable but very low-level FDG
18:53
uptake.
18:55
We sort of have to use the small size to adjust our avidity expectations, because
19:01
smaller things are just going to be less FDG avid.
19:04
They have less cells to be able to accumulate the tracer
19:08
to be able to create the signal on PET.
19:11
So if you have something that looks very suspicious, this is, in particular, for
19:16
small findings, small pulmonary nodules.
19:18
If you have something that looks suspicious by CT, don't let a negative or near
19:24
negative PET talk you out of your degree of suspicion.
19:27
You have to sort of know what to expect, and a low level of FDG uptake for a nodule
19:32
this small is sort of expected.
19:38
This atypical behavior is further illustrated by the lack of FDG avidity in the
19:42
solid component of this part solid lung cancer, which by CT remains highly
19:47
suspicious. We have
19:50
spiculated margins. This is a solid component here with some subsolid surrounding
19:56
area. This solid component is big enough that I would expect to see at least a
20:01
little bit of FDG uptake on PET, but alas, we don't.
20:05
So although based on the size of the solid portion, we would expect FDG avidity, we
20:11
don't see any on the 6 AM.
20:17
Atypical behavior on PET-CT is not limited to small lesions.
20:22
We see here this large right upper lobe lung cancer.
20:25
FDG is atypically very low. You can see it's not negative.
20:31
There is some minimal FDG uptake, which is similar to perhaps slightly less than
20:36
blood pool that's seen in the adjacent mediastinal structures.
20:40
This is a mucinous adenocarcinoma, which is an entity known to potentially cause a
20:44
false low or negative
20:47
FDG PET. The reason being that the tumor gets sort of diffused by mucin
20:52
and there are relatively less tumor cells and a lot of mucin, and so you can tend
20:58
to get very low signal in these.
21:04
This is also seen here in this companion case, the CT images of which I showed you
21:08
before. Again, only minimal FDG uptake is seen in this large left lower lobe
21:14
adenocarcinoma. Again, illustrating that atypical metabolic behavior is not limited
21:19
to small cancers, but can also be seen with large cancers.
21:27
Atypical behavior on PET-CT can sometimes prompt alternative diagnoses.
21:31
As we see here, we have a fairly decent-sized right upper lobe solid mass,
21:38
which really doesn't demonstrate very much FDG uptake.
21:41
It's very similar to background tissues.
21:44
This turned out to be a carcinoid rather than one of the typical histologies that
21:48
we've already discussed. For typical or well-differentiated carcinoids, the lack of
21:53
FDG uptake is indeed actually considered typical, whereas it would be considered
21:59
atypical for other lung cancers of a similar size.
22:03
Well-differentiated neuroendocrine tumors tend to be lowly
22:08
metabolically active. They have low Ki-67s, which is a proliferation index.
22:14
They're not using a lot of glycolytic metabolism, which is why they don't have a
22:19
lot of FDG uptake.
22:23
This is further illustrated here with this small, well-differentiated left lower
22:27
lobe carcinoid, whereas carcinoid is only faintly FDG avid, as you can see in the
22:32
middle panel with a very low SUV max.
22:35
It is intensely dotatate avid on the panel on the right, which has a
22:41
higher SUV max. So this is actually a typical appearance for
22:47
a well-differentiated carcinoid tumor, being lowly FDG avid or absent FDG avidity,
22:53
and at least moderate to intense FDG uptake on dotatate.
23:01
However, to make things more confusing, as this talk is about atypical lung
23:05
cancers,
23:07
I wanted to show you this example where not all carcinoids, well-differentiated
23:11
carcinoids, will show this typical dotatate avidity.
23:15
So in this right upper lobe carcinoid, biopsy proven to be well differentiated, the
23:20
dotatate avidity is almost completely absent.
23:23
It's very hard to appreciate anything here.
23:27
So this may be explained by the tumor escaping the sensitivity on the tracer.
23:32
But sometimes it can suggest an atypical histology or malignant degeneration where
23:37
the cells are losing their somatostatin receptor expression that are used to bind
23:42
the tracer. So this case further illustrates the fluidity between typical and
23:47
atypical metabolic behaviors that are not limited to more common lung cancer types
23:52
or even FDG, but can occur in rare types of lung cancer and using different
23:57
tracers.
24:00
This fluidity is likely to become even more prevalent as we introduce novel PET
24:05
tracers, such as FAPI, pictured here.
24:09
We may learn new or unexpected patterns of behavior in lung cancers, I think
24:13
similar to what we are currently learning about with prostate cancer from PSMA.
24:22
From a practical perspective, the following should be noted.
24:25
We must acknowledge the limitations of PET for lesion characterization purposes,
24:30
especially in atypical cancers.
24:33
As atypical cancers become more common, we should be aware of
24:39
over-reliance on the expected or typical PET manifestations.
24:44
In these cases, we can't read PET-CT in isolation, but rather integrated with our
24:50
diagnostic CT, notably when typical suspicious findings are
24:56
present, and we shouldn't delay workup based on a potentially false negative PET.
25:02
Finally, we should keep in mind that atypical behavior on PET can suggest
25:06
alternative differential diagnoses.
25:12
Shifting gears, let's talk about the detection of lung cancer.
25:18
How lung cancer is detected is also certainly shifting and changing over time.
25:23
In the recent past, lung cancer was typically detected on imaging done in a
25:26
symptomatic smoker or incidentally found on imaging
25:32
performed for another reason. The rollout of lung cancer screening programs and
25:37
other lung cancer initiatives have drastically changed this landscape.
25:41
We're seeing major impacts on stage shift and outcomes, as seen again from this
25:45
study in Taiwan. You can see that currently, or at least as of 2019, there's a
25:50
complete shift in the stages where the majority are now found in early stage,
25:56
versus just not that long ago, 20 years ago in 2006, the opposite was
26:02
true, that most lung cancers were being detected in their later stages.
26:08
These atypical but emerging detection techniques are under promising investigation,
26:13
but not yet routinely incorporated into clinical practice.
26:21
Looking at global trends in detection over the last 30 years show a typical overall
26:25
increase in incidence. This is largely driven by population growth and aging, but
26:30
with interesting and somewhat atypical decreasing trends in age-adjusted rates in
26:36
higher sociodemographic index groups. So this is really interesting, right?
26:40
While the overall incidence is increasing, we're seeing certain areas where you
26:46
have age adjustments that are showing decreases in
26:50
rates of lung cancer. This is likely reflecting the impact of screening.
26:57
So screening, which once seemed ahead of its time, is now a typical cornerstone of
27:01
modern lung cancer care. Not to say that this is being utilized to its full
27:06
potential, as I'll talk about a little bit later, that this is
27:12
woefully underutilized in many communities where it's available.
27:20
So moving on to management-
27:26
The typical mainstays of treatment are dependent on stage, location, tumor,
27:32
and patient characteristics. For some patients, we may need to employ atypical
27:37
strategies, including empiric therapy and following known or highly suspected
27:43
cancers. This, I think, is happening as patients age and
27:49
live longer. Some very slow-growing lung cancers, we may
27:54
decide that patients are more likely to die with that lesion than from that lesion,
27:59
and that initiating treatment for that particular cancer may be more harmful.
28:06
The harm may outweigh the benefit.
28:09
We also are needing to employ strategies regarding volume preservation,
28:15
especially for these patients with multiple lung cancers.
28:18
We can't just keep doing lobectomies because the patients will run out of lungs,
28:22
and obviously that's not going to be a sustainable strategy.
28:26
So even when the standard of care may be a resection or a
28:31
lobectomy, we're employing different strategies like SBRT or focused
28:37
radiation, just to be able to preserve lung volume when multiple cancers need to be
28:43
addressed. Ablation is another local strategy that can be
28:49
good for volume preservation.
28:52
One scenario that's becoming less atypical is the need for management and
28:58
recognition by radiologists, but also management of treatment-induced side effects,
29:03
particularly with the immune checkpoint inhibitors and targeted therapies.
29:08
Years ago, this wasn't something that
29:11
was occurring because we weren't using these drugs.
29:13
But now both radiologists and clinicians need to be aware of these because they
29:19
have impacts on patient management and prognosis as well.
29:29
So finally, moving on to prognosis.
29:36
So prognosis is variable by stage and type, and certainly has considerably changed
29:42
over time, really heavily influenced by advances in detection and treatments.
29:48
But as recently as the 1950s, we can see that lung cancer was typically a
29:54
deadly disease, with all-stage survival rates less than 10%.
30:00
We can see compared to up to 55% today, with rates as high as 60% to
30:05
90% in early-stage cancers. So today, while the incidence continues to
30:11
increase, so does survival, coupled with decreasing morbidity and mortality rates.
30:15
So today, in contrast to the 1950s, it's atypical for a patient to die
30:21
from an early-stage lung cancer, which is really great.
30:28
Okay, we made it. We made it around the circle of the lungs here.
30:32
So
30:34
now that we've examined present-day lung cancer from many angles and discussed what
30:38
makes cancers atypical as opposed to
30:42
more typical, we have looked at these from all different perspectives.
30:47
So what are the take-home points?
30:49
The take-home message is that lung cancer can be considered atypical for a variety
30:54
of reasons as to who it affects. While older male smokers are the dominant
30:59
demographic, other groups have emerged with unexpected and sometimes unexplained
31:04
risks. So be aware of atypical patients. How it manifests.
31:10
Histology and location have changed over time, in part due to changes in smoking
31:15
and exposure, but also environmental
31:19
factors such as pollution. So don't forget about unusual
31:25
histologies and molecular profiling is now mainstream.
31:30
It can be atypical in what it looks like. Radiographic appearance can be atypical.
31:35
There really is no one-size-fits-all model, so we have to pay attention to both
31:41
static and dynamic morphologies.
31:45
Lung cancer can be atypical in how it behaves.
31:49
Metabolic and molecular behavior of lung cancers can be atypical.
31:53
Use caution in over-reliance on typical PET findings and make sure to read in the
31:57
context of findings from other imaging.
32:01
It's particularly important with chest CT.
32:05
So it can be atypical in how we find it.
32:09
Screening and early AI programs are increasing detection, and we're seeing already
32:14
a tangible impact on prognosis and outcomes.
32:18
It can be atypical in how we address it.
32:21
Management is evolving, and we sometimes must operate outside the usual algorithm
32:25
in atypical patients and scenarios.
32:30
And it can be atypical in how it looks for patients.
32:34
Typical outcomes for lung cancer have drastically improved, especially in the
32:38
recent decades, and especially as we find cancers smaller and earlier.
32:46
Now that we've looked at lung cancer today, what does the future hold?
32:50
So regarding patients and trends, incidence is still increasing,
32:56
mainly due to population growth and aging.
33:00
We're starting to see some interesting trends in certain groups
33:06
where
33:08
age-adjusted rates are falling in high sociodemographic index regions, where more
33:13
resources are dedicated to early detection and treatment.
33:17
There may be strong preventative initiatives, tobacco taxation,
33:23
control of environmental risk factors like asbestosis and radon mitigation in
33:28
homes.
33:31
And as the global smoking rates decline in developed countries, the incidence of
33:36
lung cancer in individuals who have never smoked is stable or increasing.
33:41
We'll have to see what that looks like if it's more of a redistribution or shift
33:45
versus true increase.
33:51
I think the development of lung cancer will continue to be influenced by some fluid
33:56
environmental and patient risk factors.
34:00
What will we see with increasing pollution?
34:06
As an optimist, I'd also like to ask the question about what we could see if we
34:10
make improvements in our air quality.
34:13
Will we learn anything from
34:16
during the pandemic where a lot of
34:19
factories and industry was shut down and we saw some rebuilding of the ozone layer
34:26
and
34:28
decrease in particulate pollution?
34:33
Regarding vaping-associated lung cancers, the research right now is pretty
34:37
equivocal, but there is reason for concern regarding the oncogenicity of these
34:42
products. Lag times aren't really mature yet, so I think this remains
34:48
to be seen.
34:50
What about lung cancers related to marijuana smoking?
34:53
I mention this as recreational use has become legal in many US states, so I think
34:58
we have yet to see what the impact of that will look like.
35:04
And we're starting to see evidence of microplastics being identified in every area
35:08
of the human body, so I think we need to find out the implications in the lung for
35:13
both lung cancer and chronic interstitial lung diseases.
35:23
And then in terms of detection, as I mentioned, increases in
35:29
utilization of lung cancer screening will certainly help with finding more cancers,
35:34
finding them earlier, having better prognosis for patients, but utilization still
35:40
remains really low. In
35:43
2010, of eligible patients, only about 4% were receiving lung cancer screening
35:48
rates. This is in the US. And then
35:52
as of 2024, which is the latest data we have, it's still under 20%, which means
35:57
that over 80% of eligible patients that could be getting screened for lung cancer
36:02
are not getting that.
36:06
We also need to, as we develop these global screening programs, which are pretty
36:11
far ahead in the US, but not necessarily worldwide, we need to balance appropriate
36:18
screening guidelines and inclusion into programs with what is appropriate for
36:23
each population. The inclusion in
36:28
East Asian countries may be different than it is in the US or in other
36:34
countries. So I think we need to balance developing these population-specific
36:40
guidelines, but also Keeping in mind global harmonization so that if
36:46
programs look too different from each other, we can't really compare or combine
36:50
data to really be able to learn about this on a global level.
36:55
So I think balancing appropriate guidelines with global harmonization is important.
37:03
We're also seeing these really interesting,
37:07
often AI-driven risk prediction models that are coming out.
37:12
Sybil is just one of many, but
37:16
Sybil is a deep learning model that predicts future lung cancer risk from a single
37:22
low-dose chest CT, which is pretty cool.
37:25
There are many other models that may integrate imaging, but also talk about or
37:30
incorporate family history, smoking history, genetic predisposition,
37:37
all of the epidemiologic factors that go into lung cancer as well.
37:41
So I think these are going to continue to get better and really may change the way
37:47
that we screen patients or
37:51
are able to identify cancers earlier, which is the goal.
37:58
So prevalence is increasing as patients live longer and some patients
38:03
are developing more than one cancer.
38:08
Morbidity and mortality are decreasing as we're able to treat these earlier with
38:12
newer, safer surgical techniques, as well as radiation techniques.
38:18
I think treatments are going to continue to evolve, including the expansion of
38:23
immunotherapy and potential role for diagnostics.
38:27
We're starting to see this kind of emerge in other areas.
38:30
I wouldn't
38:32
be surprised at all if this is going to be important for lung cancer as well.
38:37
So
38:38
as we get more specific,
38:42
there may be individualized treatment profiles that take into account multiple
38:47
factors that we're able to learn about with specific patients and their molecular
38:51
profile of their tumors. So it may become less algorithmic and just sort
38:57
of following different boxes and down different paths, but really more
39:01
individualized to each specific patient with each specific tumor.
39:09
And so while incidents will likely continue to increase, I think we can hope that
39:14
outcomes will also continue to improve.
39:16
This is just some projection modeling of where we could be in 2050.
39:25
But yeah, just in summary, the advances in diagnostics and therapeutics have really
39:30
rewritten what we consider typical for lung cancer today.
39:35
What we consider typical today probably won't be typical in 20 or 40 years.
39:41
It's really highly dependent on a number of factors, some of which we discussed
39:44
today, but some of which probably have yet to be realized or discovered.
39:49
So, I look forward to updating this lecture as things change in the coming years.
39:57
So I have some references listed here, but that concludes my talk.
40:02
I did want to thank Dr. Alex McGeer for assistance in refining this talk, but I'd
40:07
be happy to take any questions.
40:13
Yeah, thank you for sharing that lecture with us today, Dr. McIntosh.
40:16
At this time, we'll open the floor for any questions from our audience.
40:19
You can submit your questions through the Q&A feature.
40:26
All right. I see one question here. What is the indication of biopsy and PET CT?
40:32
What are the situations?
40:36
Let's see. So I think this is sort of practice and region-dependent,
40:42
but
40:44
I think that CT really drives a lot of this.
40:49
And so if you have a nodule that has clearly malignant features like
40:54
spiculations or
40:58
lobulated, microlobulated contours, as we talked about with all the static
41:02
morphology features. But also if you have something that has dynamic features that
41:06
are concerning, like increases in size or density over time,
41:11
those are all indications for biopsy.
41:13
PET CT is sometimes used for lesion characterization, but oftentimes, at least I
41:19
find in my practice that
41:23
we already may have a suspicion about the nodule, and the role of the PET is really
41:27
to look at if there's nodal involvement or distant metastatic disease.
41:34
Sometimes, though, we do use PET to characterize a nodule if we're not sure if
41:38
something is
41:40
malignant or benign. An example would be rounded atelectasis.
41:45
We have a pleural-based nodule or mass that we're really
41:51
not sure if it's rounded atelectasis or malignancy, then PET CT can be helpful in
41:55
sorting those two things out.
41:58
So those are just some scenarios that might drive biopsy versus surveillance or
42:03
further workup.
42:06
All right, I see another one. Can PET scan be used as a screening tool?
42:11
So right now, at least in the US, it's not really used that way.
42:15
There is a lot of excitement about whole body MRI, which would be a
42:21
screening tool. And in some places, there are programs where you
42:27
can sort of buy a PET CT for yourself.
42:31
You can do a self-pay as a screening exam.
42:36
So there are isolated cases of that, but right now it's not really being used that
42:40
way. As a person who reads primarily PET CT, I think that
42:46
you really need a high-quality CT to interpret your PET,
42:53
which depending on the specific protocols or cameras that you have available to
42:58
you, you may or may not have the ability to have a high-quality CT along with a
43:03
PET. So I think PET's really a sort of a
43:09
tool in the toolbox that helps us work out findings that we see on other imaging.
43:15
That's where I see its primary use.
43:21
Dr. McIntosh, if you're looking for the Q&A menu,
43:25
there's a dropdown there next to the
43:31
settings for your mic and stuff, I believe.
43:34
I see. Thank you. I was looking in the chat.
43:38
Let's see. Okay. I'm sorry, I didn't mean to ignore what was going on here.
43:44
Do you think it is likely Pop Leo has atypical lung cancer?
43:47
I believe he's a non-smoker. So yeah, I think the lung cancer arising in
43:54
a non-smoker is certainly atypical, but becoming more recognized.
43:58
I saw something yesterday. I think they've released information that it's an
44:02
adenocarcinoma, which is one that certainly can be associated with non-smokers.
44:08
I would say I probably, in my personal experience, haven't seen many cases of
44:11
squamous cell that have been outside of smoking population. So, okay.
44:19
Please, what is the role of MR spectroscopy in lung cancer or malignant nodules?
44:25
This is a great question. I do not know.
44:30
I don't read any MR in my current practice, but
44:35
the ability to sort of differentiate different types of tissue by MR spectroscopy
44:41
is certainly exciting and promising.
44:43
So, I'm sorry I don't have an answer for you, but I'm sure it's worth looking into.
44:48
There must be papers out there about it.
44:51
Okay. Should non-smokers be screened for atypical lung cancers, though?
44:56
That's a great question. I think right now the screening guidelines are really
45:02
heavily driven by smoking history, but as we discussed,
45:07
we see lung cancer in non-smokers, so there has to be something there specifically
45:11
or particularly in these East Asian females.
45:14
So I think when we're creating screening programs, those things are going to have
45:20
to be incorporated for certain populations.
45:23
So,
45:25
if there's a strong family history or environmental factors like pollution,
45:31
then maybe those things should be considered in designing lung cancer screening
45:35
programs and guidelines.
45:38
Let's see. Frequently, we encounter tiny nodules and pass it off as healed
45:43
granuloma. So when to suspect and when to follow up for malignancy?
45:47
Yeah, this is really tricky as we sort of deal with one nodule at a time.
45:54
One thing that can be really helpful is if it's calcified, those tend to be benign.
45:59
And so if there's calcification within a small nodule, we tend to just kind of put
46:04
that in that bucket. And they don't necessarily require further follow-up.
46:09
We use the lung cancer screening
46:13
lung-RADS as a guide for us as well, when we're formally screening for lung cancer.
46:19
And when we're not and we find
46:21
lung nodules on CT, we use the Fleischer Society guidelines.
46:25
Both of those classify
46:28
calcified nodules as being benign.
46:30
So the guideline systems that we have in place can be really helpful for sort of
46:36
managing these. So
46:39
when we think something's a granuloma, we kind of stop there.
46:43
Let's see. "From your
46:49
experience, what steps can be taken to distinguish between infection versus
46:53
malignancy in CT lung, especially if surrounded by consolidation opacity with air
46:59
bronchogram?" Yeah, this can be really tricky.
47:03
I think features like,
47:06
as we talked about today, if something is growing in a mass-like configuration,
47:11
that tends to be more concerning for cancer versus if it's just filling alveolar
47:15
spaces, that tends to be more consistent with infection.
47:20
But in particular, that left lower lobe adenocarcinoma that I showed you guys,
47:24
really it is actually just cancer that's filling the alveolar spaces.
47:30
So some clues that you can use to differentiate between these two, and I think we
47:34
miss these all the time because we just say that they look like pneumonia, is if
47:38
they don't respond to antibiotics and if they continue to get worse over time.
47:42
These are frequently diagnosed on bronchoalveolar lavage because we're not able to
47:47
identify them by imaging because they look the same.
47:49
But if they're not improving, that may direct you to recommend
47:55
lavage to look for something that's atypical, like cancer.
48:00
Let's see. "Is there
48:06
in the US something like criteria Fleischer Society guidelines to follow up the
48:10
unclear lesions?" So yeah, I touched on the Fleischer Society guidelines
48:15
before in that
48:20
the guidelines work very well if your lesions fit into a box,
48:26
right? Is this a solid nodule? Is this a calcified nodule?
48:30
Is this a cystic nodule, which isn't completely addressed yet.
48:34
But when things fall into those boxes, then there's answers of what to do with it
48:38
next. Does this need follow-up? If it does, what's the time interval that we need
48:42
it? How far should we follow it out?
48:44
But these unclear lesions are a little bit tricky, right?
48:49
So I think if there's a chance that something could be malignant, it's reasonable
48:54
to continue to follow it. Use everything that you have available to you.
48:58
Look at static morphology, dynamic morphology.
49:02
Certainly, if there's any changes over time.
49:05
What's very interesting is when we think about changes over time, we tend to think,
49:10
"Oh, okay, if a nodule is increasing in size, that's suspicious, right?" But
49:15
they're not common. There are cases of nodules that,
49:21
particularly ones that start out as sub-solid or ground-glass, and over time,
49:26
as they get more solid, the solid tissue in the
49:32
center can sort of retract, and pull the tissue in around it.
49:37
And so sometimes you have a nodule that actually shrinks over time.
49:42
But if it's increasing in density, then you sort of have to balance those two, and
49:47
that's a suspicious finding.
49:50
Let's see. "Because it's often hard to differentiate between
49:55
benign nodules, granulomas, and cancer." Yeah.
49:59
So we talked about this one a little bit.
50:01
And I think that's the whole point of these Fleischer Society guidelines, right?
50:04
Is that when we see a nodule, we often don't know.
50:08
If it's calcified, we can feel good about that.
50:10
But sometimes granulomas are non-calcified, and so we don't know, is this a
50:14
non-calcified granuloma? Is this a benign nodule that's occurring for some other
50:19
reason, or is this the earliest manifestation of lung cancer?
50:22
Because they pretty much all start as a small nodule,
50:26
or an area of increased density.
50:29
And so when we're looking at these in isolation, especially the first time that we
50:33
find them, the first CT a patient has, it can be really difficult to differentiate
50:38
them, which is why we have these systems of follow-up.
50:42
And we sometimes stratify the follow-up based on just what it looks like on
50:47
imaging. But other times we use clinical information, like with Fleischer Society
50:52
guidelines, there's different
50:55
algorithms or pathways for patients that are considered high risk versus low risk.
50:59
And smoking is
51:02
something that's considered in that.
51:05
All right. "Does a lung lesion limited by a fissure indicate it to be a more benign
51:10
lesion than a malignancy?" This is a great question.
51:14
So if you have a nodule that's located within a fissure, especially if it
51:20
has a triangular shape or concave margins to it, rather
51:26
than bulging or convex,
51:30
that is a very good appearance for an intrapulmonary lymph node, which is going to
51:35
be a benign lesion.
51:38
But you can certainly get lung cancers that arise adjacent to a fissure or the
51:44
pleural surface. And one feature that I'm always looking at when I find a
51:49
pulmonary nodule is, does this have any impact on the fissure or the pleural
51:55
surfaces nearby?
51:58
Because nodules that are benign tend to just grow in a
52:04
little mass-like configuration.
52:06
They push things that are nearby out of the way, versus primary lung
52:11
cancers are very fibrotic, and they tend to drag the tissue in around them, which
52:16
is why they become spiculated. Those spiculations are reflective of central
52:20
fibrosis and retraction. And so if you have a nodule that's on
52:26
or next to a fissure and you see any sort of fissural distortion where it's being
52:31
tented, pulled, any sort of architectural distortion there, that is a red flag for
52:36
a cancer. So that's certainly a feature that would head me in more the direction of
52:42
a malignancy.
52:46
Let's see. There's a question here about biopsy, which I won't take because I don't
52:50
do any interventions myself, so I won't be able to answer it with any expertise.
52:55
But, "When suggesting an adenocarcinoma diagnosis, do you specify AAH,
53:02
AAIS, MIA, or leave it non-specific?" I love that somebody asked this question
53:07
because this is a teaching point that I really drive home with our trainees here at
53:13
UMass. I like to be as specific as possible.
53:17
And part of that is for reasons that we discussed in the talk, is that we have
53:22
patients that are living longer with multiple lesions.
53:25
And it's really tricky for the clinicians when you give them a report that says
53:29
there's three or four lung cancers, and they sort of don't know what to do with
53:34
that. Do they address all of them? Is there one that looks worse than the others?
53:38
Is there one that's going to be potentially life-threatening for the patient versus
53:43
one that we could maybe safely watch that may not become an issue during the rest
53:49
of their expected life?
53:52
And so yes, there's a few really great papers out there that give
53:58
good graphic examples of-- so AAH is atypical adenomatous hyperplasia,
54:04
which is a
54:07
pre-invasive adenocarcinoma spectrum type lesion where it's completely
54:12
ground-glass and it's less than 5 millimeters00.
54:15
So those lesions are often very safe-- not safe, but those lesions are often
54:20
followed because they're small and they're not invasive yet.
54:24
The next step along that spectrum is adenocarcinoma in situ.
54:27
And so this is often characterized by an entirely ground-glass lesion, but it's
54:32
greater than 0.5 centimeters, and they say up to about 3 centimeters.
54:36
So again, this falls in the pre-invasive part of the spectrum.
54:41
It's not an invasive cancer yet
54:44
But as these develop punctate solid components, then they cross into the next part
54:49
of the spectrum, which is minimally invasive adenocarcinoma.
54:53
And this is where management may be indicated.
54:58
And then as you get more and more solid component to your nodule, then those are
55:02
just clearly invasive adenocarcinomas.
55:05
So when I'm reading a case, I will be as specific as possible.
55:09
I'll say, "Slight increase in size of the two-centimeter purely
55:15
ground-glass nodule, which was one centimeter five years ago.
55:20
This likely represents an adenocarcinoma in situ." And I think that when you give
55:24
the clinician that information, then they know how to manage that nodule.
55:28
They say, "Okay, this is still pre-invasive." In an older patient with
55:34
poor lung function and high risk for biopsy, they may say, "We're just going to
55:38
follow this." It might be a different story in a 45-year-old young patient that
55:44
this thing is continuing to grow, and they're going to want to take care of it
55:47
before they're going to have to lose a lot of lung for it.
55:49
So it's very patient-specific, but I think
55:53
we have the information and the data to support that the appearance can really
55:58
reflect the histology. And, of course, it's not perfect.
56:02
Tissue is the issue, but I really encourage people to be as specific as possible
56:07
because it really helps with the management, especially in older patients and
56:10
especially patients with multiple lesions.
56:17
Looks like you cleared through all those questions real quick. Good job.
56:21
Let's see. There was one more here in the chat that I didn't get to.
56:28
Long-standing cysts can transform into malignancies, so for how long should we
56:33
follow? So it's a great question, and it is, I think, still up in the air
56:38
about what the management for these is.
56:40
So Lung-RADS was just updated in 2022, which is the lung cancer screening
56:45
guidelines that we use in the US, and it's the first time that the management for
56:51
the cystic lesions has been incorporated, but it sort of treated them as a
56:56
separate entity. But as we saw in the presentation today, you might
57:02
not just have a cystic nodule or a cyst.
57:06
A cyst could be a component of a complex nodule or mass that has both solid and
57:12
cystic components. So if a nodule has cystic components, do you let the
57:18
solid part of it drive the management, or should there be something separate for
57:22
the cystic component? So I think we need to do a better job at
57:28
characterizing what the cystic part means.
57:31
And, if a nodule is predominantly cystic versus it has minor cystic components,
57:37
are those going to be managed differently?
57:39
So,
57:40
right now we consider a cyst with imperceptible or very thin walls to be
57:47
safe to watch.
57:50
But if there's any sort of wall thickening or nodularity, these are features of
57:55
malignancy that need to be either watched very carefully or sampled and managed.
58:02
And with the cystic ones, PET-CT is often limited because if it's a
58:08
predominantly cystic lesion, we're not really expecting solid tissue to have FDG
58:14
uptake. And so it's like the added value of PET with the
58:20
cystic lesions, either entirely or mostly cystic lesions, is sort of not the
58:26
same as it is for solid lesions. So,
58:30
I'm hoping that the next updates of Fleischner and Lung-RADS will more formally
58:36
address cysts and cystic lesions about how to follow them.
58:41
Let's see. A patient with a known carcinoid tumor in the abdomen and a known SPN.
58:47
Do you prefer dotatate PET or FDG?
58:52
So yeah, this is a specific situation.
58:54
So in the US, often insurance will not reimburse a dotatate PET until you
59:00
actually have tissue. And the reason is because dotatate PET is going to bind to
59:06
those somatostatin receptors, which are overexpressed in the well-differentiated
59:10
tumors. If you have a poorly differentiated tumor,
59:15
they tend to lose their somatostatin receptor expression, and dotatate will be
59:19
negative. So a lot of insurance companies say, "We want to know what type of
59:23
neuroendocrine tumor or carcinoid tumor this is before we go ahead with our PET."
59:29
And so for a well-differentiated, you're going to choose dotatate.
59:32
And for a poorly differentiated, you're going to choose an FDG.
59:34
So if you have a patient with a known carcinoid tumor in the abdomen and they have
59:39
a pulmonary nodule, I think depending on what insurance will allow, either is
59:44
reasonable, but I think most people would probably start with an FDG, especially if
59:49
it's a solid nodule. Because
59:53
for it to be metastatic disease and be singular is not impossible, but a solid
59:58
pulmonary nodule that has suspicious features, I think is probably more likely, if
60:02
you play the odds, to be a lung cancer.
60:06
Let's see. We are at 1:00. There's a couple more questions. I'm not sure, Ben.
60:10
I'm happy to take a couple more, or up to you guys.
60:15
We are at time.
60:21
I will leave that to you, I think.
60:23
Okay.
60:24
Maybe these last couple, and then we'll-
60:28
Okay
60:28
... call it a day.
60:29
How does ILD affect interpretation of lung nodules? So that is interesting.
60:35
I think formally, in terms of the guidelines, there really isn't anything that
60:40
says, oh, you would manage a nodule differently in this patient who has ILD versus
60:45
this patient that doesn't. But personally, in my practice, I think the presence of
60:50
ILD makes me think outside the box a little bit more.
60:53
If there's increasing solid tissue, but it's not really a nodule, and it's more
60:58
sort of sheet-like or non-mass-like, I think to myself, could this be a cancer?
61:04
And does it just not look typical because the background that it's growing on is so
61:10
abnormal?
61:12
So personally, for me, I tend to think outside the box a little bit more and will
61:18
include things that in a patient with normal lung, I would say, "Hmm, that's
61:23
probably scarring or atelectasis." But in a patient with ILD, I might be a little
61:27
bit more suspicious about it. Ask for follow-up or recommend a PET or something
61:32
like that.
61:34
Okay. And here's the last one. Do you see a large ground-glass opacity about
61:40
three centimeters being stable from more to three to five years or longer in your
61:43
experience? Yeah. So a lot of the guidelines sort of talk about following things
61:49
out to two or three years. But
61:53
in my practice, I have definitely seen things that change or that are stable for
61:59
three or four years. And then, if you go back and you see something from 10 years
62:04
ago, then you say, "Oh, there definitely has been a change here." So I think
62:10
that there are very, very slow-growing adenocarcinoma spectrum type lesions.
62:16
They usually start as an AH or an AIS that
62:22
the guidelines say, oh, you can stop following after two to three years.
62:26
But,
62:27
I will say in my personal practice, I've definitely seen ones that have been
62:31
followed for longer, or we have an old comparison, and we do see changes after that
62:37
time. So stability of two to three years makes you feel better, but may not be
62:42
enough. So I think the more we learn about lung cancer screening and the longer
62:47
we're tracking these lesions, we'll learn more about that.
62:51
So,
62:53
yes, I hope that answered your question, but thank you guys so much for your
62:58
attention and interest, and these were some really great and interesting questions
63:03
that I'm going to add some things to my
63:06
lecture to address some of these. So thank you.
63:10
Yeah. Dr. McIntosh, thanks for that lecture and for answering all those great
63:13
questions. And thanks to everyone who joined us today.
63:17
Okay.
63:18
Be sure to join us next week on Thursday, October 22nd at 12:00 PM Eastern, where
63:23
Dr. Steven Pomeranz will deliver a lecture entitled, "Deep Dive into Foot and Ankle
63:29
MRI." You can register for that at medallity.com and follow us on social media for
63:33
updates on future noon conferences. Thanks again, and have a great day.